20 articles
A completed exploratory trial evaluates whether a specialized compression garment can reduce discomfort and improve quality of life in pelvic lymphedema patients.
New diagnostic chip analyzes blood exosomes to detect early lung spread of bone cancer, potentially improving treatment outcomes.
A first-in-human Phase 1/2 trial of ISB 1442 in relapsed/refractory multiple myeloma was halted before completion.
Phase 3 trial compared therapeutic vaccine OSE2101 to chemotherapy in 219 lung cancer patients after immunotherapy failure.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
French study explores how tiny cellular packages in blood could predict cancer recurrence and guide treatment decisions.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Small study explores cerebrospinal fluid exosomes to better diagnose breast cancer spread to brain and spinal cord.
A Phase 1/2 NCI trial tested PANVAC vaccinia and fowlpox vaccines plus immune booster sargramostim in advanced colorectal, breast, and ovarian cancers.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
A completed French trial explores how gut and airway microbiota, blood, and sputum biomarkers relate to immunotherapy outcomes in metastatic NSCLC.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.
A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
French researchers test intraperitoneal nivolumab after surgery and heated chemotherapy for advanced ovarian cancer patients.
